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PABSTRACT
Background: Treatment of sleep disorders in visu-
ally impaired children is complicated by a complex
pathophysiology, a high incidence of sleep disorders in
this population, and a dearth of management options.
The significant impact on the health of these children
and distress to their caregivers warrant a systematic
assessment of the published literature on therapeutic
approaches.
Objective: This systematic review aims to assess the
current therapeutic options in the management of sleep
disorders in visually impaired children to identify
knowledge gaps and guide future research.
Methods: A search of primary literature was con-
ducted using the bibliographic databases PubMed
(1980–August 2010), EMBASE (1990–August 2010),
Science Citation Index Expanded (1990–August
2010), and CINHAL (1992–August 2010) and the
Cochrane Central Register of Controlled Trials
(CENTRAL). Additional studies were identified
through snowballing search techniques (manually by
earching retrieved references and electronically by us-
ng citation-tracking software). Search terms included
ehavioral treatment, children, circadian rhythm, hypno-
edatives, intellectual disability, light therapy, mela-
onin, phototherapy, random allocation, randomized
ontrolled trial (RCT), sleep disorder, and visual im-
pairment. Randomized and quasi-randomized clinical
168rials of therapeutic options (behavioral treatment,
ight therapy, melatonin, or hypnosedatives) used in
articipants aged 3 months to 18 years who had both a
isual impairment and a sleep disorder were included.
ndependent extraction of articles was performed by
authors using predefined data fields, including
uality of the therapeutic options, based on the
trength of Recommendation Taxonomy evidence-
ating system.
Results: Two RCTs were retrieved for melatonin,
with improved effect on sleep latency (P  0.019 and
 0.05, respectively). However, separate analysis for
visual impairment was not conducted. No RCTs were
retrieved for behavioral intervention, light therapy, or
hypnosedatives. Three studies using behavioral ther-
apy (2 case reports and 1 case series) anecdotally
showed improvement in sleep habit. No improvement
in sleep rhythm was observed with a case series apply-
ing light therapy as an intervention.
Conclusions: Children with visual impairment and
sleep disorders are a heterogeneous patient group,
making diagnosis and treatment difficult. RCTs on
treatment options remain in their infancy, with a lack
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S.A. Khan et al.of evidence for appropriate therapeutic strategies. Tri-
als across a range of selected diagnoses need to be con-
ducted with adequate sample populations to differen-
tiate the efficacy of 4 different treatment modalities
(behavioral therapy, light therapy, melatonin, and
hypnosedatives) as agents for improving sleep. (Clin
Ther. 2011;33:168–181)© 2011 Elsevier HS Journals,
nc. All rights reserved.
Key words: children, chronobiology, sleep disorder,
isual impairment.
INTRODUCTION
Sleep is integral to a child’s development, and visual
impairment adversely affects this fundamental biolog-
ical function.1 In the late 1970s, Kestenberg2 high-
ighted the importance of altered sleep disorders in vi-
ually impaired children. Numerous aspects of human
hysiology and behavior are dominated by 24-hour
hythms that have a major impact on health and well-
eing.3 Circadian rhythms in biological systems are
undamental to life, with sight, light exposure, and
ight-dark perception playing important roles in ad-
usting behavioral and physiologic processes.
Approximately 25%of all children experience some
ype of sleep disturbance during childhood.4 This num-
ber is closer to 80% in those with intellectual disability
and visual impairment.5 Visually impaired children are
specially vulnerable, as they often have additional dis-
bilities, including hearing impairment, cerebral palsy,
nd intellectual disability—all of which can produce
leep disorders in their own right.1 Non–24-hour
leep–wake syndrome (N24HSWS) is common in indi-
iduals who are totally blind, half of whom are ad-
ersely affected.6-8 Sleep disorders such as N24HSWS
are also common in adolescence9 and can be com-
ounded by poor sleep hygiene and age-related changes.
he cyclic nature of sleep disorders results from a mis-
atch or poor coupling between the child’s attempts to
ive in accordance with the behavioral zeitgeber (liter-
lly, “time-giver”) of a 24-hour “social day” and the
hild’s internal circadian system, which runs on a non–
4-hour intrinsic period.10
The pathogenesis of circadian rhythm sleep disor-
ders is complex, with numerous mechanisms working
simultaneously. Signaling molecules that play a key
role in circadian setting include serotonin (5-HT), pi-
tuitary adenylate cyclase-activating peptide (PACAP),
neuropeptide Y (NYP), -aminobutyric acid (GABA),
February 2011and melatonin, with suprachiasmatic nucleus (SCN)
and cholinergic inputs also involved (Figure 1).11-14
Figure 2 illustrates the classic process C and process H
for the sleep–wake rhythm.15,16
Melatonin is a neurohormone secreted from the pi-
neal gland during the night that plays an important
role in the regulation of sleep via the circadian sleep–
wake rhythm.17 Onset of secretion coincides with tim-
ing of the increase in nocturnal sleepiness. The SCN
involved with melatonin production is sensitive to the
presence of zeitgebers or environmental cues, the most
powerful of which are light and darkness. Responses to
these cues are impeded in children with visual impair-
ment.1 Disturbed sleep patterns have been associated
ith abnormal melatonin production in adults,18 and
delays in the secretory pattern of melatonin in children
with severe visual impairment.19
The repercussions of pediatric sleep disorders ex-
tend beyond behavioral and growth difficulties to sub-
stantial socioeconomic and health burdens on caregiv-
ers. They can lead to inability to provide continuous
care, impaired performance, and increased accidents at
work, home, and during travel,20 hence the critical
eed for evidence-based, effective therapies. The objec-
ive of this systematic review is, therefore, to evaluate the
herapeutic options for the management of sleep disor-
ers in visually impaired children, based on Preferred Re-
orting Items for Systematic Reviews andMeta-analyses
uidelines21 and to identify knowledge gaps to guide fu-
ture research. Therapeutic options were evaluated, based
on the Strength of Recommendation Taxonomy evi-
dence-rating system.22
METHODS
Types of Studies
Randomized and quasi-randomized clinical trials on
therapeutic options (behavioral treatment, light therapy,
melatonin, or hypnosedatives) were included. No lan-
guage or publication status restrictions were imposed.
Types of Participants
Participants between 3 months and 18 years of age
with visual impairment and a sleep disorder were con-
sidered. Sleep disorder was defined as a disorder of
sleep initiation, maintenance, or scheduling.Visual im-
pairment was defined as loss of vision due to ocular
conditions or damage to the posterior visual pathways
and visual cortex of cortical, retinal, or mixed origin.
169
Clinical TherapeuticsTypes of Intervention and Outcome Measures
Trials evaluating the therapeutic effect of behavioral
treatment, light therapy, melatonin, or hypnosedatives
were included. Primary outcome measures were sleep
timing and sleep scheduling. Secondary outcome mea-
sures were adverse events of any therapeutic option and
quality of life.
Information Sources
Asearch of primary literaturewas conducted using the
bibliographic databases: PubMed (1980–present), EM-
BASE (1990–present), Science Citation Index Expanded
(1990–present), CINHAL (1992–present) databases and
Cochrane Central Register of Controlled Trials (CEN-
TRAL). Additional studieswere identified through snow-
balling search techniques (manual searching of retrieved
references and electronic searching by using citation-
tracking software). Search terms included behavioral
Figure 1. Circadian clock regulation through signaling
dian setting. The circadian clock is regulated
adenylate cyclase-activating peptide (PACAP
The pineal hormone melatonin is a chief reg
blind individuals, the photic input to the pin
rhythm, slightly different from that of a 24-h
responsive to phase adjustment by glutamate
that regulate sleep and wakefulness.treatment, children, circadian rhythm, hypnosedatives,
170intellectual disability, light therapy, melatonin, photo-
therapy, random allocation, randomized controlled
trial (RCT), sleep disorder, and visual impairment. Ad-
ditional search terms used were benzodiazepine, chlo-
ral hydrate, nitrazepam, and nonbenzodiazepines.
Search Strategy
The following search strategy was used in PubMed
to evaluate the trials involving melatonin in visually
impaired children:
1. Melatonin/
2. adolescent/ or child/ or child, preschool/ or in-
fant/
3. (baby or babies or infant$ or child$ or boy$ or
girl$ or toddler$ or preschool$ or pre-school$ or
teen$ or schoolchild$ or adolescen$ or juve-
nil$).tw.
ules. Several signaling molecules play a key role in circa-
sensitive during daylight to serotonin (5-HT), pituitary
ropeptide Y (NYP), and -aminobutyric acid (GABA).
of circadian rhythm during dawn and dusk. In totally
and is absent, and the circadian clock free runs with a
eriod. At night, the suprachiasmatic nucleus (SCN) is
PACAP and by cholinergic inputs (acetylcholine [Ach])molec
and
), neu
ulator
eal gl
our p
and4. 2 or 3
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S.A. Khan et al.5. Visually Impaired Persons/
6. exp Vision Disorders/
7. ((vision$ or visual$) adj3 (handicap$ or dis-
abili$ or disabl$ or impair$ or disorder$)).tw.
8. blind$.tw.
9. 5 or 6 or 7 or 8
10. exp Sleep Disorders/
11. insomni$.tw.
12. (sleep adj3 (disorder$ or problem$ or pat-
tern$)).tw.
13. (wakefulness or waking).tw.
14. 10 or 11 or 12 or 13
15. 1 and 4 and 9 and 14
16. randomized controlled trial.pt.
17. controlled clinical trial.pt.
18. randomized.ab.
19. placebo.ab.
Figure 2. A schematic representation of the “oppo
sleep results from the interaction of home
sent sleep load, which is determined by
increases during waking and declines as
suprachiasmatic nucleus, the circadian p
line represents the resulting course of sle
was created based on data from previous20. drug therapy.fs.
February 201121. randomly.ab.
22. trial.ab.
23. groups.ab.
24. 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
25. humans.sh.
26. 24 and 25
27. 15 and 26
Study Selection
Eligibility assessment was performed independently in
an unblended standardized manner by 2 reviewers. Dis-
agreement (if any) between reviewers was resolved by
consensus.
Data Collection Process
A data extraction sheet was developed, and the pilot
was tested on randomly selected studies and refined
process” model. Alternation of wakefulness and
tic (H) and circadian (C) process. Process H repre-
emporal sequence of behavioral states. Process H
ensues. In contrast, Process C is regulated by the
aker, without regard to behavioral state. The solid
ss as a function of time during the day. This figure
blished studies.15,16nent
osta
the t
sleep
acem
epine
ly puaccordingly. One author extracted data from included
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Clinical Therapeuticsstudies, and 2 authors checked the extracted data. Dis-
agreement was resolved by discussion between the 2
authors. If no agreement could be reached, it was
planned for a third author to adjudicate. Informationwas
extracted fromeach included trial on (1) characteristics of
trial participants (age, type of sleep disorder, visual im-
pairment), (2) type of intervention (type, dose, duration,
and frequency), and (3) type of outcome measure. To
explore variability in study results (heterogeneity), it was
hypothesized that effect size may differ according to the
methodological quality of the studies.
RESULTS
The study selection process and justification are pro-
vided in a flow diagram (Figure 3) and Table I, respec-
tively. Two RCTs on melatonin met the review inclu-
sion criteria, but none of the behavioral interventions,
hypnosedative, or light therapy studies retrieved met
the inclusion criteria.
The 2 melatonin studies were randomized, con-
trolled, and published in English. Neither study was
designed specifically to evaluate response in children
with visual impairment. The study by Coppola et
al23 involved 25 children with intellectual disability,
only 4 (16%) of whom were visually impaired, and
the study by Dodge and Wilson24 also included only
(20%) children with visual impairment in the 20
ith intellectual disability recruited for the study.
atients were recruited from multiple centers. The
ntervention received was placebo, 5 mg mela-
onin,23 or 3, 6 or 9 mg melatonin.24 Age ranges
ere from 3.6 to 26 years23 and from 1 to 12 years,24
with the intervention lasting 8 weeks. Primary out-
comes assessed were sleep latency and night waking,
with secondary measures of daytime mood and side
effects. The assessments were measured by caregiv-
ers, who maintained a sleep diary throughout the
study. Quality of life was not an outcome in either
study, although anecdotal comments are described.
Table II highlights potential bias in the 2 melatonin
studies.
Meta-analysis was not feasible because of the
marked variability in study designs, participants, inter-
ventions, and reported outcome measures. Neither of
the 2 RCTs on melatonin examined responses to inter-
ventions of the visually impaired population separately
from those of the recruitment population of children
with intellectual disability. We therefore focused on
descriptive analysis of study results and limitations. s
172Owing to a lack of RCTs, there is only limited discus-
sion of other interventions. Table III provides evi-
dence-based ratings of different treatment modalities
using the SORT evidence-rating system.22
DISCUSSION
Despite the lack of RCTs, behavioral treatments such
as bedtime parenting practices are widely used in visu-
ally impaired children.25 Various behavioral tech-
iques such as sleep scheduling, chronotherapy, ex-
inction, graduated extinction, scheduled waking,
ositive bedtime routine, bedtime fading, response
ost, positive reinforcement, parent education, advice,
nd support have been tried in children with sleep dis-
rders of multiple origins.26
Chronotherapy, in the context of behavioral inter-
vention, has been tried in children with visual impair-
ment in 3 studies, 1 case series, and 2 case reports. In 1
case report27 a 2-year-old boy with visual impairment
isplayed sustained improvement, based on a sleep di-
ry, for the 6 months following the institution of treat-
ent (a schedule of 9:30 PM bedtime with a set bedtime
routine; a 6:30 AM wakeup time; naptime at 1 PM; and
meals at 8 AM, noon, and 6 PM). On dechallenge, there
as a drift in sleep pattern that improved gradually
fter reimplementation of the strict daily schedule. In
ontrast, Okawa et al28 evaluated the impact of forced
wakening in a case series of 4 visually impaired chil-
ren. Therapy was ineffective in 1 case and question-
ble in 2 cases. Although the treatment was effective in
child with a free-running sleep–wake rhythm, she
as forced to stay awake by being kept in a sitting
osition, and her wake pattern conformed to the 24-
our rhythm only after she began taking nitrazepam.
n the remaining case report,29 sleep maintenance was
mproved in a 4.5-year-old girl with visual impairment
nd a gradual extinction procedure, from being awake
5 minutes (range 0–150 minutes) during the baseline
eriod to sleeping “on time” (range 0–63 minutes)
ostintervention.
These studies provide weakly positive and anec-
otal support for the use of behavioral interventions
o improve sleep, but objective data remain insuffi-
ient to recommend widespread application. How-
ver, the importance of preventive measures in the
orm of parental training with children at special
isk is an important area for research. When admin-
stered by trained caregivers, techniques such as the
etting of consistent time cues that include meals and
Volume 33 Number 2
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S.A. Khan et al.bedtime routines may be helpful in the case of visu-
ally impaired children.
Light therapy is a widely cited intervention to man-
ageN24HSWS.9,30,31 However, only one case of a con-
enitally blind child with circadian sleep–wake rhythm
isorder who received light therapy (2000 lux admin-
stered at 6:00 AM for 1 hour to entrain the usual 24-
our rhythm of sleep–wake) was found. This interven-
ion was unsuccessful.28 It is therefore not surprising
hat light therapy alone has failed to find a place as a
ajor treatment option in this cohort. It is difficult to
reate a placebo/comparative dummy when evaluating
he effect of light therapy, and even more difficult to use
linded study designs when bright light therapy is the
ctive intervention. Thus, studies of interventions with
igorous design are difficult. Early studies also failed to
each consensus on a standardized approach to lux pa-
ameters for the active treatment, duration of the trial,
nd characteristics of the placebo control conditions.32
Lack of funds and sponsorship to support the devel-
Figure 3. Flow chart for the selection of studies. Se
therapy (B).opment and testing of this intervention is a major con- a
February 2011tributing factor to the paucity of effective studies.32
Although adverse effects such as headache, eye strain,
nausea, and agitation have been reported in the results
of adult studies,33,34 pediatric pharmacovigilance data
are lacking.
Behavioral intervention and light therapy have not
yet provided good evidence as synchronizers for circa-
dian rhythms in children with visual impairment. This
may be secondary to difficulties with study design or
with lack of effectiveness; therefore, research into
pharmacotherapeutic interventions has become more
prevalent. One promising therapeutic agent for the
treatment of N24HSWS is melatonin. This compound
has been used commonly in children with visual
impairment.23,24,35–40
One large case series36 of 100 patients treated a
pecific cohort of children with visual impairment. Ini-
ially, a small number of the children (data not pro-
ided) were treated with melatonin or placebos in a
ouble-blind, crossover, randomized design. However,
n of evidence for behavioral therapy (A) and light
(continued)lectiofter the initial studywas completed, the placebo phase
173
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Clinical Therapeuticswas discontinued. Outcomes were measured with sub-
jective sleep diaries only. The authors reported, at vari-
able doses, that children were generally asleep after 30
minutes, with sustained improvement for 2 to 4 weeks
after 3 to 4 days. However, treatment failure was re-
ported in 17% of the children, and objective data are
lacking.
Two studies23,24 that incidentally recruited children
with visual impairment in a population of children
with intellectual disability did not separately analyze
the visually impaired group. A study by Copolla et al,23
verified the clinical efficacy of melatonin in children
with intellectual disability, with or without epilepsy.
Out of the total study population (N  25), 4 were
visually impaired. A significant effect on sleep latency
was reported as measured by sleep logs (P  0.019).
The resulting mean sleep latency appeared to decrease
with melatonin (0.3 hour) compared with those of the
baseline (1.6 hours) and placebo (0.7 hour) phases, and
no effect on nocturnal wakingwas observed. However,
Figure 3. (continued). Flow chart for the selection
hypnosedatives (D).it is unclear whether the P value refers to melatonin
174versus baseline or melatonin versus placebo, thus mak-
ing interpretation of this report difficult. Responses
(sleep latency, total sleep time during the night in
hours, diurnal sleep time in hours, night awakenings,
and early arousal [number of patients in which this
condition was present]) were seen at doses of 3 mg
(29.2% of patients), 6 mg (45.8% of patients), 9 mg
(20.8% of patients), and 12 mg (4.2% of patients).
These doses are higher than what has been recom-
mended anecdotally in other populations.41
It should be noted that information from Copolla et
al23 was lacking on what threshold was considered a
response.” The authors suggest an increase in total
leep time, both on melatonin and on placebo versus
aseline (7.9, 7.0, and 4.4 hours, respectively). How-
ver, the P values were above the range to be consid-
ered statistically significant. The number of early
arousals (number of patients) were not statistically sig-
nificant (P  0.123, Fisher exact test) as observed in
patients on melatonin, placebo, and baseline (2, 6, and
udies. Selection of evidence for melatonin (C) andof st13, respectively). Importantly, no significant adverse
Volume 33 Number 2
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S.A. Khan et al.effects were noted, even at higher doses. Variable ef-
fects, both positive and negative, were seen in patients
with a concurrent seizure disorder. All returned to
baseline after melatonin was ceased. Approximately
half of families reported better daytime functioning,
but statistical data were not provided.
The other study, by Dodge and Wilson,24 explored
the safety and efficacy of synthetic melatonin in the
treatment of sleep problems in 20 children with devel-
opmental disabilities, 4 of whom were visually im-
paired. In comparing the mean sleep latency between
Table I. Excluded studies on melatonin.
First Author, Title, Reference
Jan J. The treatment of sleep disorders with melatonin
Neurol. 1994;36:97–107.
Palm L. Long-term treatment in blind children and yo
circadian sleep–wake disturbances. Dev Med Child Neur
319–325.
Espezel J. The use of melatonin to treat sleep–wake rh
children who are visually impaired. J Vis Impair Blind. 1
Schmitt-Mechelke TH. Melatonin in the treatment of
neuropaediatric patients. Schweiz Medizinische Wochensc
1997;127(Suppl 87):9.
Hung JC. The use of melatonin in the treatment of sle
in children with neurological or behavioural disorders
Pract. 1998;3:250–256.
Jan JE. Clinical trials of controlled-release melatonin in
sleep–wake cycle disorders. J Pineal Res. 2000;29:34–3
Table II. Risk of bias—studies on melatonin.
Trials
Concealment
of
Randomization
RCT
Stopped
Early
Pati
Blin
Copolla et al23 Yes No Ye
Dodge and
Wilson24
Yes No Ye
RCT  randomized controlled trial.
Note: These studies recruited children with intellectual disab
impairment was incidental. No separate analysis was perform
study population.February 2011different treatment conditions, all but 2 children
showed a decrease in sleep latency when receiving
melatonin as opposed to placebo or baseline. The de-
crease in mean sleep latency with melatonin as sug-
gested by the authors was significant at P  0.05 by
nalysis of variance. Mean sleep latency was 0.7 hour,
.2 hours, and 1.2 hours with melatonin, placebo, and
aseline, respectively. As in the aforementioned study,
t is not clear whether a direct comparison was made
etween melatonin versus placebo from the provided
esults, making interpretation difficult. Interestingly,
Reason(s) for Exclusion
Med Child Inadequate randomization; case series
dults with
97;39:
Inadequate randomization and
blinding
disorders in
0:43–50.
Inadequate randomization
problems in Case series; not blinded
turbances
iatr Pharm
Inadequate randomization
ren with Comparison of melatonin formulation
Health
Care
Providers
Blinded Data Collectors Blinded
Outcome
Assessors
Blinded
No Information not available No
No Information not available No
ecruitment of children with intellectual disability and visual
us, results may be biased for reasons of heterogeneity of the. Dev
ung a
ol. 19
ythm
996;9
sleep
hrift.
ep dis
. J Ped
child
9.ents
ded
s
s
ility. R
ed; th175
i
s
d
i
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Clinical Therapeuticstotal sleep time improved (P  0.007) with melatonin
(8.1 hours) as compared with baseline (7.1 hours), but
not when compared with placebo (7.8 hours). No dif-
ference in the mean number of night awakenings was
noted with the melatonin (0.9), placebo (0.7), and
baseline (0.9) groups. However, both of these studies
failed to analyze children with visual impairment as a
separate cohort.
Populations with intellectual disability may have
other attributes that confound these results when ex-
amining effects in children with visual impairment.
Melatonin appears to entrain free-running rhythms
and causes phase-advance shifts when administered in
the early evening and a phase delay when given in the
early morning.42 Soporific in pharmacologic doses, it
needs to be administered at the same time each day
(close to the desired bedtime) to reinforce the asso-
ciation between the circadian and social day.42 Prior
nformation on circadian phase is important for
cheduling melatonin therapy. As sleep–wake cycle
isturbances are often associated with disturbed tim-
ng of melatonin secretion, the measurement of endog-
nous melatonin may be helpful.43 It is not clear how
these effects relate to those observed in the 2 aforemen-
Table III. SORT evidence-based rating for therapeuti
Clinical Status
Behavioral approach is promising based on anecdota
randomized controlled studies, and these strategies ar
implement in visually impaired children and caregivers
Light therapy: There are no randomized controlled tri
impaired children. Apart from lack of information on
duration of phototherapy has not been determined in
children, and a duration response curve is nonexistent
Melatonin is a potential option in the short-term man
N24HSWS in visually impaired children. Data on effic
however, inconclusive.
Hypnosedatives are prescribed in some cases and as a
behavioral approaches, but there have been no rando
studies in visually impaired children.
Evidence rating based on Strength of Recommendation Taxo
as A, B, and C. A consistent and good-quality patient-orien
evidence; C consensus, usual practice, opinion, disease-or
prevention, or screening; N24HSWS non–24-hour sleep–wtioned RCTs,23,24 as no time of administration for
176melatonin was reported. It is also difficult to ascertain
whether the effect of melatonin on sleep latency related
to a change in sleep phase or to a soporific effect, or
indeed to both. Thus, regardless of co-morbidities, fu-
ture research should aim to ascertain sleep phase re-
sponses by additional measures such as wake times,
body temperature, and the like. This would help deter-
mine whether children with visual impairment are
preferentially affected by melatonin toward either se-
dation or an adjustment in sleep phase.
Measurement of dim-light melatonin onset is con-
ducted in research settings that include measuring
plasma or salivary melatonin concentrations. Endoge-
nous melatonin exhibits a significant interindividual
and age-related variability in its pharmacokinetics.44
There is a need for simple, reliable, and sensitive meth-
ods for circadian testing. Besides, there is an inconsis-
tent ratio between serum and salivary concentra-
tions.45 None of the clinical trials evaluated in Table I
measured melatonin profiles as part of any diagnostic
and therapeutic screening. The current methods to
identify circadian abnormalities rely on subjective
measures obtained from interviewing the patient and
family members. Light therapy requires clear informa-
ions in sleep disorders in visually impaired children.
Evidence Rating References
rts but lacks
cult to
C 27, 28, 29
visually
cy, the ideal
lly impaired
C 28
ent of
nd safety is,
B 23, 24
junct to
controlled
C 28
(SORT), wherein the strength of recommendation is rated
tcome; B inconsistent or limited-quality patient-oriented
evidence, or case series for studies of diagnosis, treatment,
yndrome.c opt
l repo
e diffi
.
als in
effica
visua
.
agem
acy a
n ad
mized
nomy
ted ou
iented
ake stion on the circadian profile of the patient.46 Without
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S.A. Khan et al.valid circadian testing, the amount of light required for
these patients remains unknown and is relegated to
guesswork. Information on the circadian period would
help in screening and evaluating the cause of circadian
abnormalities, with possible implications for sleep dis-
order therapy. However, determination of the circa-
dian period is a long, laborious process not directly
associated with clinical application.47
Melatonin access varies markedly by country, rang-
ing from nonprescription to orphan drug status.48 As it
s an endogenous substance, it cannot be patented;
ence, the lack of financial incentives for its commer-
ial development. The European Medicines Agency
nd Australian Drug Evaluation Committee (ADEC)
ave recently approved Circadin,49 a sustained-release
formulation of melatonin for primary insomnia in el-
derly patients, on the basis of subjective sleep measure
data. It was appropriate that these agencies did not
accept extrapolation of adult data to the elderly popu-
lation. This approach should be emulated in the pedi-
atric setting. The quality control of melatonin as a ther-
apeutic substance is not universally standardized, and
impurities in the product are a potential concern.50
Chemical analogues of melatonin have been developed
recently, such as agomelatine, but the trials of this drug
are being done on adults and not for the purposes of
managing sleep disorders.51-53 Some analogues are un-
ergoing clinical trials but not yet in visually impaired
hildren with sleep disorders.
For the past decades the hypnosedatives—benzodi-
zepines and nonbenzodiazepines, such as barbitu-
ates, tricyclic antidepressants, antihistamines, buspi-
one, zolpidem, and zopiclone—have been usedwidely
or sleep induction and maintenance. Most studies
ave been conducted in adults presenting with insom-
ia with no psychiatric comorbidities.54 Benzodiaz-
pines act as allosteric modulators of the GABAA re-
eptor complex, improving the binding efficiency of
he main inhibitory neurotransmitter of the CNS,
amely, GABA. In the context of parasomnias, the
rime use for benzodiazepines in children is for sleep
isorders,55,56 but they have also been used to manage
ight terrors and partial arousals. In addition, they
ave been prescribed for blind children with circadian
hythm disturbances and for intellectually handi-
apped children with sleep disturbances.57,58 How-
ver, no RCTs in these settings were retrieved. In 1 case
eries,28 nitrazepam was administered to 4 congeni-
ally blind children. Based on subjective measures, the a
February 2011leep–wake rhythm was improved; however, these chil-
ren were also receiving behavioral intervention and an-
iconvulsant therapy (sodium valproate and phenobarbi-
al). It shouldbenoted that nitrazepamhas a longhalf-life
nd presents with a risk of accumulation.59
Although not specifically labeled for sleep disorders,
the shorter-acting midazolam is available in the United
States in a child-friendly liquid formulation, with dos-
ing recommendations based on pediatric data.57 Al-
though no longer favored, chloral hydrate has been
prescribed for children with sleep-onset delay, but
there remains some concern regarding safety.56 Intel-
lectually handicapped children with sleep disorders
and blind children with circadian rhythm disturbances
also have been prescribed chloral hydrate for manage-
ment of sleep disorders; however, no data are provided
on its efficacy or safety.56,58
Prescription hypnosedatives have neither an ADEC
nor a US Food and Drug Administration approval for
insomnia in adolescents 18 years. International
guidelines no longer advocate over-the-counter hyp-
nosedatives, such as antihistamines, for children 2
years of age.60,61 A recent national survey62 on the use
of pharmacotherapy for insomnia in child psychiatry
practice revealed a number of prescription medications
such as -agonists, trazodone, sedating antidepres-
ants, benzodiazepines, short-acting hypnotics, and
ntihistamines specifically prescribed for insomnia.
owever, concerns about adverse effects and lack of
mpirical support regarding efficacy were cited as sig-
ificant barriers to their use.
Over-the-counter medications such as melatonin
ere recommended by one third of the respondents in
his survey. Although off-label use of the hypnoseda-
ives, as an adjunct to behavioral modification, is often
onsidered in the setting of insomnia, these drugs may
urther exacerbate an already complex situation by
ausing confusional states at night and rebound or
angover effects during the day in children, regardless
f any underlying visual impairment or intellectual dis-
bility.63,64 The risks associated with long-term use of
ypnosedatives (particularly benzodiazepines similar
o nitrazepam), such as tolerance, dependence, in-
reased abuse potential, and withdrawal symptoms,
annot be overlooked.
Nonbenzodiazepines like zaleplon and zolpidem
ave a relatively short half-life and no demonstrable
orning hangover and may be preferable to benzodi-
zepines with longer half-lives, especially in the pedi-
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Clinical Therapeuticsatric population.41 However, there are no studies of
safety or efficacy in children with visual impairment. A
recent systematic review65 on insomniamanagement in
adults concluded that the clinical benefits of benzodi-
azepines were almost certainly inflated by reporting
bias and needed to be offset by the evidence that these
drugs pose a significant risk. Current pharmacothera-
peutic research on insomnia management is moving
away from the major inhibitory GABAA receptor sys-
tem toward modulating more subtle endogenous path-
ways that control the sleep–wake cycle.54 Such ap-
roaches may be more appropriate for helping
articular subpopulations suffering from sleep disor-
ers with a mismatched or poorly coupled sleep–wake
ycle.
One main objective of this systematic review is to
dentify significant research and knowledge gaps in this
ulnerable pediatric population. Across the interven-
ions, studies have failed to measure changes in func-
ional health status, and health-related quality of life
easures have been neglected despite being one of the
arameters used for defining insomnia per the Diag-
ostic and Statistical Manual of Mental Disorders
DSM IV) criteria.63 Studies failed to analyze the base-
line circadian rhythm before initiating therapy in such
populations. Over the past 3 decades there has been little
progress in sleep and circadian testing,66 especially in
children. Such data are lacking in children, healthy or
sick. Studies failed to provide long-term evidence of effi-
cacy (hypnosedatives/melatonin/light therapy) through
longitudinal measures of sleep maintenance. It would be
useful to look at whether any of these interventions can
provide a long-term solution (12 months or more) and
duration of effect.
Most studies conducted using melatonin and hyp-
nosedatives have been of relatively short duration (the
maximum being 8 weeks). This means that long-term
safety data are lacking. A recent consensus statement
on the pharmacologic management of insomnia in chil-
dren and adolescents concluded that studies on the
safety and efficacy of the pharmacologic treatment of
insomnia are urgently needed.25 Current options do
not provide optimal balance between the tolerability
and the efficacy profile, especially in the areas of sleep
maintenance and long-term use.67
Editorial comment68 has focused attention on the
eed to improve undergraduate and postgraduate
edical training in the area of sleep medicine. Without
etailed knowledge of sleep physiology and patho-
178hysiology, the development of rational management
trategies for sleep disorders in children is difficult.
hen medications are used they typically do not have
egulatory approval for pediatric use or for a specific
leep disorder. Most pharmacologic guidelines were
eveloped for sleep disorders in adults and have been
xtrapolated empirically to children. At times, a deci-
ion to use medication in a child may be made not only
o assist the patient, but also to help the parents or
ther family members cope. There is a lack of special-
zed training in sleep disorders for allied health
rofessionals.
Noncompliance with medication is often an impor-
ant issue in children with behavioral problems and
ust influence the development of therapies in this
roup. Drug interactions and adverse effects from
olypharmacy must also be taken into consideration.
he development of easy-to-swallow chewable or liq-
id forms of sleep medication is important in these
oung patients. The integration of behavioral and
harmacologic treatmentsmay yield better patient out-
omes. Improved training programs can play a lead
ole in enhancing pediatrician and health care team
nowledge of the pharmacologic treatment of sleep
isorders in children.68
This systematic review combines data across studies
to estimate treatment effects with more precision than
is possible in a single study. Although the process of
conducting this review was robust, the major limita-
tion was lack of consistent measures across the patient
population, interventions, and outcome definitions
across studies, leaving us with a lack of evidence upon
which practice recommendations can be based.
CONCLUSIONS
Children with visual impairment and sleep disorders
are a heterogeneous clinical group, which makes diag-
nosis and treatment difficult. The number of controlled
studies that qualify for systematic review are limited.
Across the 4 domains of treatment modalities that in-
clude behavioral therapy, light therapy, melatonin,
and hypnosedatives, there are limited numbers of con-
trolled studies that qualify for a systematic review or
meta-analysis. A number of anecdotal reports suggest
behavioral therapy as effective; however, evidence is
weak owing to a lack of well-designed studies. Because
of the difficulty in developing a rigorous study design,
there is limited evidence for light therapy as an inter-
vention. Case series and anecdotal reports suggest a
Volume 33 Number 2
1S.A. Khan et al.favorable effect on sleep initiationwith the use of mela-
tonin, but the evidence is not strong. Studies on mela-
tonin are poorly designed without clear comparisons
between the therapeutic effect of melatonin and a pla-
cebo. Some authors suggested an improvement on
sleep latency, but the results were unclear. No signifi-
cant effect was observed when comparing sleep latency
with placebo on total sleep time and nocturnal arousal.
Concerns about adverse effects and lack of empirical
support regarding efficacy are significant barriers to
the use of hypnosedatives. The safety profile of hyp-
nosedatives urges caution in extrapolating adult data
to children.
This review has identified the potential gap in re-
search and practice over decades of limited studies in
this specialized and vulnerable patient population of
children with visual impairment. It is necessary to co-
ordinate basic research, clinical research, health care
practice, and public education, in addition to address-
ing policy and organizational issues, to improve thera-
peutic rationalization and outcomes in the manage-
ment of sleep disorders for this highly vulnerable
pediatric population.
Implications for Practice
Consistency in outcome measures of sleep and cir-
cadian pattern across different treatment modalities
will be helpful for systematically evaluating and com-
paring end points in clinical trials in visually impaired
children with sleep disorders. There is a need to vali-
date subjective outcome measures used in RCTs in this
population using standard quality-of-life and behav-
ioral parameters as a component of the clinical study
alongside objective measures, such as actigraphy.
Managing sleep disorders in children with visual im-
pairment is a specialized area with limited indication
for treatment modalities. Collaborative guidelines for
management should be established. Multicenter col-
laboration through defined teams of developmental pe-
diatricians, sleep physicians, and other health care pro-
fessionals and researchers is essential, as many centers
may not be employ specialized experts. Participation of
collaborators with experience in evidence-based prac-
tice research is desirable owing to the lack of protocol
on therapeutic modalities.
Implications for Research
Further diagnostic information on a child’s circa-dian phase, period, amplitude, and susceptibility to
February 2011phase-shifting, utilizing sleep and circadian measure-
ment parameters, will greatly help in developing ratio-
nal therapies. Further research should also concentrate
on using and comparing the effects of standardized
subjective and objective measurements (eg, sleep diary,
polysomnography, actigraphy) within and between the
studies for consistent primary and secondary outcome
evaluation. In a specialized subpopulation, such as
children with visual impairment, multicenter collab-
oration may be crucial in achieving a level of evi-
dence to support or disprove the use of pharmaco-
logic modalities.
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